Here’s what you should know:
1. The companies are going to conduct a phase II, open-label, randomized, non-comparative study to examine Effector’s small molecule MNK1/2 inhibitor eFT508 — a cancer treatment that uses the body’s immune system to fight cancer.
2. The inhibitor will be paired with avelumab in patients with relapsed or refractory CRC. The companies will also evaluate eFT508 alone as a monotherapy.
3. Researchers will randomize patients two-to-one into combo-and monotherapy arms.
4. The companies will begin the study in the third quarter of fiscal year 2017.
More articles on gastroenterology:
AGA on Better Care Reconciliation Act: ‘Patient access to care in peril’
GI center to know: University Gastroenterology
Takeda’s CEO under pressure & more — 5 GI company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.